10 Best Biotech Stocks to Invest In According to Billionaires

The race to secure the next blockbuster medicine is giving biotech investors two opportunities to assess: the value a treatment could generate and the price a larger drugmaker might pay to acquire it. Patent expirations are pushing pharmaceutical companies to replenish their pipelines, while advances in obesity, oncology and other treatment areas are attracting capital. Neither opportunity removes the central challenge: determining whether the science, funding and commercial prospects...